Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
作者信息
Bouwmeester Romy N, Wetzels Jack F M, van de Kar Nicole C A J
机构信息
Radboud University Medical Center, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Department of Pediatric Nephrology, Nijmegen, The Netherlands.
Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Nephrology, Nijmegen, The Netherlands.
出版信息
Kidney Int Rep. 2024 Apr 8;9(6):1929. doi: 10.1016/j.ekir.2024.02.1442. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗治疗移植后血栓性微血管病：益处未得到证实：对马里蒂等人《移植后血栓性微血管病管理中的“先使用依库珠单抗”》的回应
Kidney Int Rep. 2024 Apr 8;9(6):1929. doi: 10.1016/j.ekir.2024.02.1442. eCollection 2024 Jun.
2
A Caution Against the Use of C5b-9 Endothelial Assay to Support Eculizumab Therapy: A response to Maritati : "Eculizumab first" in the management of posttransplant thrombotic microangiopathy.关于使用C5b-9内皮细胞检测来支持依库珠单抗治疗的警示：对马里蒂的回应：移植后血栓性微血管病管理中的“先使用依库珠单抗”
Kidney Int Rep. 2024 Mar 1;9(5):1538. doi: 10.1016/j.ekir.2024.02.1434. eCollection 2024 May.
3
Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab.依库珠单抗成功逆转难治性移植后血栓性微血管病
Indian J Nephrol. 2024 Mar-Apr;34(2):191-194. doi: 10.4103/ijn.ijn_345_22. Epub 2023 Apr 4.
4
"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗优先用于移植后血栓性微血管病的管理
Kidney Int Rep. 2024 Jan 10;9(4):982-993. doi: 10.1016/j.ekir.2024.01.013. eCollection 2024 Apr.
5
Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.依库珠单抗可改善因抗磷脂综合征复发导致的移植后血栓性微血管病，但不能预防慢性血管改变。
Am J Transplant. 2013 Aug;13(8):2179-85. doi: 10.1111/ajt.12319. Epub 2013 Jun 13.
6
Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature.依库珠单抗治疗药物诱导的血栓性微血管病：文献综述范围。
Thromb Res. 2023 Apr;224:73-79. doi: 10.1016/j.thromres.2023.02.012. Epub 2023 Mar 2.
7
Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.儿童自体造血细胞移植后血栓性微血管病：依库珠单抗治疗幸存者发生重要终末器官功能障碍的报告。
Biol Blood Marrow Transplant. 2019 May;25(5):e163-e168. doi: 10.1016/j.bbmt.2018.12.840. Epub 2019 Jan 11.
8
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.依库珠单抗治疗吉西他滨诱导的血栓性微血管病：法国血栓性微血管病参考中心的经验。
BMC Nephrol. 2021 Jul 21;22(1):267. doi: 10.1186/s12882-021-02470-3.
9
Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.依库珠单抗治疗移植相关性血栓性微血管病的疗效和安全性：系统评价和荟萃分析。
Front Immunol. 2021 Jan 20;11:564647. doi: 10.3389/fimmu.2020.564647. eCollection 2020.
10
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.依库珠单抗清除率的可变性需要进行药效学监测，以优化造血干细胞移植后血栓性微血管病的治疗。
Biol Blood Marrow Transplant. 2016 Feb;22(2):307-315. doi: 10.1016/j.bbmt.2015.10.002. Epub 2015 Oct 9.
引用本文的文献
1
Exuberant Endothelial C5b-9 Formation in Recurrent and Posttransplant Thrombotic Microangiopathy.复发性及移植后血栓性微血管病中内皮细胞C5b-9形成活跃
Kidney Int Rep. 2024 Aug 22;9(11):3318-3323. doi: 10.1016/j.ekir.2024.08.014. eCollection 2024 Nov.
本文引用的文献
1
"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.依库珠单抗优先用于移植后血栓性微血管病的管理
Kidney Int Rep. 2024 Jan 10;9(4):982-993. doi: 10.1016/j.ekir.2024.01.013. eCollection 2024 Apr.
2
Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity.肾移植后血栓性微血管病：一种诊断不足且可能可逆的病症。
Front Med (Lausanne). 2021 Apr 8;8:642864. doi: 10.3389/fmed.2021.642864. eCollection 2021.
3
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.肾移植后补体突变相关的新发血栓性微血管病
Am J Transplant. 2008 Aug;8(8):1694-701. doi: 10.1111/j.1600-6143.2008.02297.x. Epub 2008 Jun 28.
4
Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.接受环孢素相关溶血尿毒综合征和血栓性微血管病的肾移植受者的随访
Transplant Proc. 2005 May;37(4):1889-91. doi: 10.1016/j.transproceed.2005.02.112.
5
De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.肾移植受者的新发血栓性微血管病：溶血性尿毒症综合征与局限性肾血栓性微血管病的比较
Am J Kidney Dis. 2003 Feb;41(2):471-9. doi: 10.1053/ajkd.2003.50058.
Zotero 插件